Page last updated: 2024-08-24

mk 0591 and Adverse Drug Event

mk 0591 has been researched along with Adverse Drug Event in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arruda, JM; Baccei, C; Bain, G; Chapman, C; Correa, L; Darlington, J; Evans, JF; Hutchinson, JH; King, CD; Lee, C; Li, Y; Lorrain, D; Prasit, P; Prodanovich, P; Rong, H; Santini, A; Stock, N	1

Other Studies

1 other study(ies) available for mk 0591 and Adverse Drug Event

Article	Year
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103). Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19 Topics: 5-Lipoxygenase-Activating Proteins; Animals; Asthma; Carrier Proteins; Dogs; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds; Humans; Indoles; Inhibitory Concentration 50; Leukotriene B4; Membrane Proteins; Mice; Propionates; Protein Binding; Rats; Structure-Activity Relationship	2009

Article

Year

5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).

Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19

Topics: 5-Lipoxygenase-Activating Proteins; Animals; Asthma; Carrier Proteins; Dogs; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds; Humans; Indoles; Inhibitory Concentration 50; Leukotriene B4; Membrane Proteins; Mice; Propionates; Protein Binding; Rats; Structure-Activity Relationship

2009